Be Clinical, an Indian skincare startup focused on evidence-led formulations, has raised ₹6 crore in a seed round led by V3 Ventures, with participation from Titan Capital. The funding arrives as consumer demand grows for clinically validated, ingredient-forward skincare within India’s expanding beauty and personal care market.
Science-led positioning and product focus
Founded in May 2025 by Hemangi Dhir, Be Clinical markets itself as a science-first skincare brand with a core emphasis on anti-ageing solutions. The company prioritises in‑vivo testing, clinical validation and dermatologist-led formulation over marketing-driven claims, seeking to differentiate on demonstrable efficacy.
The product range covers face, body and scalp care, addressing age-related concerns using active ingredients at measured dosages validated for visible results. By investing in research and transparent claims, the brand aims to build durable consumer trust in a market often sceptical of unsubstantiated performance assertions.
Use of funds
Be Clinical says the ₹6 crore will mainly strengthen its research and development capabilities. Planned investments include expansion of the in‑house formulation team and broader clinical testing across current and pipeline products to deepen evidence around product performance.
A portion of the capital will be deployed to enhance manufacturing infrastructure — adding machinery to raise production efficiency and maintain quality consistency as volumes scale. The company also intends to upgrade packaging formats to better preserve ingredient stability while reinforcing its clinical positioning.
Early traction and market context
Although a young brand, Be Clinical reports having served over 25,000 customers, reflecting rising consumer acceptance of clinically driven skincare in India. This uptake aligns with a wider trend of better-informed buyers who scrutinise ingredients, formulations and safety profiles before purchase.
India’s skincare market has historically been dominated by mass-market and international players that may not be optimised for local skin types and climatic conditions. Be Clinical seeks to bridge that gap by combining products tailored to local needs with global clinical standards.
Competitive landscape and outlook
The company operates in a crowded segment comprising legacy global brands and rapidly scaling Indian direct‑to‑consumer players. Its stated point of differentiation is a focus on measurable outcomes over cosmetic promises, positioning it within the premium, results‑oriented category.
Investor support from V3 Ventures and Titan Capital underscores growing confidence in science-backed consumer brands in India. With this seed round, Be Clinical is positioned to accelerate product innovation, improve operational capabilities and deepen engagement with consumers prioritising evidence-based skincare.
